The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Targeting adenosine A2A receptors in Parkinson's disease
Open accessAbstract
The adenosine A2A receptor has emerged as an attractive non-dopaminergic target in the pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS distribution. It is highly enriched in striatopallidal neurons and can form functional heteromeric complexes with other G-protein-coupled receptors, including dopamine D2, metabotropic glutamate mGlu5 and adenosine A1 receptors. Blockade of the adenosine A2A receptor in striatopallidal neurons reduces postsynaptic effects of dopamine depletion, and in turn lessens the motor deficits of PD. A2A antagonists might partially improve not only the symptoms of PD but also its course, by slowing the underlying neurodegeneration and reducing the maladaptive neuroplasticity that complicates standard 'dopamine replacement' treatments. Thus, we review here a prime example of translational neuroscience, through which antagonism of A2A receptors has now entered the arena of clinical trials with realistic prospects for advancing PD therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Role and Regulation of Adenosine in the Central Nervous System
Dunwiddie, T. V., & Masino, S. A. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.31 · Cited by 1,632
Pathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 844
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., & Thiel, M. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104731 · Cited by 696
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90173-9 · Cited by 650
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00285.x · Cited by 641
Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
Self-citationCiruela, F., Casadó, V., Rodrigues, R. J., Luján, R., Burgueño, J., Canals, M., Borycz, J., Rebola, N., Goldberg, S. R., Mallol, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3574-05.2006 · Cited by 590
Schiffmann, S. N., Jacobs, O., & Vanderhaeghen, J. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08257.x · Cited by 530
Cited by
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Dichotomous dopaminergic control of striatal synaptic plasticity
Shen, W., Flajolet, M., Greengard, P., & Surmeier, D. J. (2008) · Science · doi:10.1126/science.1160575 · Cited by 1,190
Surmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Self-citationNeural Control of the Lower Urinary Tract
de Groat, W. C., Griffiths, D., & Yoshimura, N. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130056 · Cited by 553
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Impact of GPCR Structures on Drug Discovery
Congreve, M., de Graaf, C., Swain, N. A., & Tate, C. G. (2020) · Cell · doi:10.1016/j.cell.2020.03.003 · Cited by 375
Adenosine A2A receptor mediates microglial process retraction
Orr, A. G., Orr, A. L., Li, X.-J., Gross, R. E., & Traynelis, S. F. (2009) · Nature Neuroscience · doi:10.1038/nn.2341 · Cited by 362
Canas, P. M., Porciúncula, L. O., Cunha, G. M. A., Silva, C. G., Machado, N. J., Oliveira, J. M. A., Oliveira, C. R., & Cunha, R. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3728-09.2009 · Cited by 357
Adenosine signaling and function in glial cells
Boison, D., Chen, J.-F., & Fredholm, B. B. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.131 · Cited by 306
Self-citationShen, W., Tian, X., Day, M., Ulrich, S., Tkatch, T., Nathanson, N. M., & Surmeier, D. J. (2007) · Nature Neuroscience · doi:10.1038/nn1972 · Cited by 292
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 287
Adenosine A 2A Receptor as a Drug Discovery Target
de Lera Ruiz, M., Lim, Y.-H., & Zheng, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011669 · Cited by 276
ATP as a multi-target danger signal in the brain
Rodrigues, R. J., Tomé, A. R., & Cunha, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00148 · Cited by 259
Timing is not everything: neuromodulation opens the STDP gate
Pawlak, V. (2010) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2010.00146 · Cited by 255
Multi‐state modeling of G‐protein coupled receptors at experimental accuracy
Heo, L., & Feig, M. (2022) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.26382 · Cited by 215
Caffeine as a factor influencing the functioning of the human body-friend or foe?
Rodak, K., Kokot, I., & Kratz, E. M. (2021) · Nutrients · doi:10.3390/nu13093088 · Cited by 188
Koizumi, S., Ohsawa, K., Inoue, K., & Kohsaka, S. (2013) · Glia · doi:10.1002/glia.22358 · Cited by 184
Adenosine, caffeine, and sleep–wake regulation: state of the science and perspectives
Reichert, C. F., Deboer, T., & Landolt, H. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13597 · Cited by 183
“The A2A receptor was thus proposed to provide a promising target as add-on treatment to ameliorate motor and non-motor symptoms such as fatigue in Parkinson's disease (Schwarzschild et al., 2006).”
BackgroundNicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Adenosine receptor neurobiology: overview
Chen, J.-F., Lee, C.-F., & Chern, Y. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00001-5 · Cited by 119
Pandolfo, P., Machado, N. J., Köfalvi, A., Takahashi, R. N., & Cunha, R. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.011 · Cited by 118
Astrocyte–neuron interplay in maladaptive plasticity.
Papa, M., De Luca, C., Petta, F., Alberghina, L., & Cirillo, G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.010 · Cited by 104
Istradefylline reduces memory deficits in aging mice with amyloid pathology
Orr, A. G., Lo, I., Schumacher, H., Ho, K., Gill, M., Guo, W., Kim, D. H., Knox, A., Saito, T., Saido, T. C., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.10.014 · Cited by 87
Cocaine exposure modulates dopamine and adenosine signaling in the fetal brain
Kubrusly, R. C. C., & Bhide, P. G. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.09.007 · Cited by 40
G Protein-Coupled Receptor Heterocomplexes in Neuropsychiatric Disorders
Moreno, J. L., Holloway, T., & González-Maeso, J. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-386931-9.00008-8 · Cited by 30
Pathological Synaptic Plasticity in Neurological Disorders
Jin, C., & Karlstedt, K. (2025) · Synaptic Plasticity - Neurobiology, Neuroanatomy, and Clinical Neuroscience · doi:10.5772/intechopen.1007753 · Cited by 1
Metadata
- Authors
- Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J.-F., & Morelli, M.
- Venue
- Trends in Neurosciences
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 29
- Issue
- 11
- Pages
- 647-654
- ISSN
- 0166-2236 (ISSN-L)
- OpenAlex
- W1987380827
- Cited by
- 433
- References
- 76
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.